Le Lézard
Classified in: Business
Subject: ATY

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sibanye Stillwater Limited - SBSW


NEW YORK, March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sibanye Stillwater Limited ("Sibanye" or the "Company") (NYSE: SBSW). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Sibanye and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On February 21, 2024, Sibanye issued a press release providing a "production update and trading statement" for 2023. Among other items, Sibanye disclosed that its 2023 profit fell as much as 91%, citing a sharp decline in platinum group metal ("PGM") prices. Sibanye also said that it recognized impairments totaling 47.45 billion rand (approximately $2.5 billion), citing again the impact of weakening metal prices as well as operational challenges at its U.S. PGM and South African gold operations, and also at the Sandouville nickel refinery in France. 

On this news, Sibanye's American Depositary Receipt ("ADR") price fell $0.32 per ADR, or 6.96%, to close at $4.38 per ADR on February 21, 2024.

Then, on March 5, 2024, Sibanye reported its financial and operating results for 2023. Among other items, Sibanye reported a full-year net loss of $2.03 billion, booking an impairment charge of $2.58 billion primarily related to the Company's Montana palladium project, which the Company attributed primarily to the impact of weakening metal prices. 

On this news, Sibanye's ADR price fell $0.38 per share, or 8.72%, to close at $3.93 per share on March 5, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP


These press releases may also interest you

at 16:10
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of...

at 16:10
Despegar.com, Corp. ("Despegar" or the "Company"), Latin America's leading travel technology company, today announced unaudited financial results for the three-months ended March 31, 2024 ("first quarter 2024" or "1Q24"). Financial results are...

at 16:10
Build-A-Bear Workshop, Inc. today announced that the Company will report first quarter fiscal 2024 results for the period ended May 4, 2024, on Thursday, May 30, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will...

at 16:10
Ulta Beauty, Inc. today announced that its financial results for the first quarter of fiscal 2024 will be released Thursday, May 30, 2024, after the market closes. The Company will host a conference call at 4:30 p.m. ET / 3:30 p.m. CT to discuss the...

at 16:10
Take-Two Interactive Software, Inc. today reported results for the fourth quarter and fiscal year 2024, ended March 31, 2024. For further information, please see the fourth quarter and fiscal 2024 results slide deck posted to the Company's investor...

at 16:10
Exicure, Inc. , has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force,...



News published on and distributed by: